The safety and efficacy of high dose ketamine in the treatment of RSD / CRPS are unknown. Patients who are volunteering to participate in high dose ketamine trials are placing themselves at very high
personal risk and expense.
The Food and Drug Administration (FDA) in the United States has approved ketamine as a sole anesthetic agent for general anesthesia, but not for the
duration and purpose in
As of July 5, 2005, the high dose ketamine trial has been completed in 27 volunteers in Germany. However, this study intervention has been reported in only 10 people. Although the German study was reported at
a medical meeting in the United States and
published in an abstract, there is
no peer reviewed scientific report
in the medical literature.
In this video presentation, Elizabeth Jones recounts how her recent participation in the high dose ketamine trial in June 2005 has given her a "second lease" on
life. Other patients have reported similar results.